CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | organic halide salt |
|
Accession: | CHEBI:51069
|
browse the term
|
Synonyms: | related_synonym: | organic halide salts |
|
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions affects localization |
ISO |
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein] |
CTD |
PMID:15985612 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:38701902 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Duloxetine Hydrochloride binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Cd48 |
CD48 antigen |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of CD48 protein] |
CTD |
PMID:38701902 |
|
NCBI chr 1:171,508,989...171,532,825
Ensembl chr 1:171,509,577...171,532,826
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein |
CTD |
PMID:29100959 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
multiple interactions |
ISO |
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:29134401 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of IL1A protein] |
CTD |
PMID:38701902 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
EXP |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 2:55,301,814...55,488,157
Ensembl chr 2:55,325,982...55,488,157
|
|
G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
multiple interactions |
EXP |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 9:32,226,002...32,255,640
Ensembl chr 9:32,226,003...32,255,646
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
multiple interactions |
EXP |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr16:94,545,839...94,798,719
Ensembl chr16:94,549,495...94,798,560
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects localization |
ISO |
Duloxetine Hydrochloride affects the localization of NFE2L2 protein |
CTD |
PMID:29134401 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of PRL protein |
CTD |
PMID:17606668 |
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased expression of VEGFA protein] |
CTD |
PMID:38701902 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr14:66,370,685...66,390,397
Ensembl chr14:66,372,488...66,390,397
|
|
G |
Chrna3 |
cholinergic receptor, nicotinic, alpha polypeptide 3 |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr 9:54,917,401...54,933,846
Ensembl chr 9:54,917,395...54,933,846
|
|
G |
Chrna4 |
cholinergic receptor, nicotinic, alpha polypeptide 4 |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] |
CTD RGD |
PMID:9454827 PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339
|
|
G |
Chrna7 |
cholinergic receptor, nicotinic, alpha polypeptide 7 |
multiple interactions increases response to substance increases activity |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:10216184 |
|
NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein] |
CTD RGD |
PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939
|
|
G |
Chrnb4 |
cholinergic receptor, nicotinic, beta polypeptide 4 |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] |
CTD |
PMID:9454827 |
|
NCBI chr 9:54,935,438...54,956,236
Ensembl chr 9:54,935,438...54,956,063
|
|
G |
Tnf |
tumor necrosis factor |
increases activity |
ISO |
TNF results in increased activity of Dimethylphenylpiperazinium Iodide |
CTD |
PMID:15086448 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
decreases activity |
ISO |
thiazolyl blue results in decreased activity of ABCB1 protein |
CTD |
PMID:15451006 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Aco2 |
aconitase 2, mitochondrial |
multiple interactions |
EXP |
[Calcium results in increased activity of ACO2 protein] which results in increased reduction of thiazolyl blue; [Potassium deficiency results in decreased activity of ACO2 protein] which results in decreased reduction of thiazolyl blue |
CTD |
PMID:12548706 |
|
NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
thiazolyl blue results in increased activity of CASP3 protein |
CTD |
PMID:22401948 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
thiazolyl blue results in increased activity of CASP8 protein |
CTD |
PMID:22401948 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide quinone reductase 2 |
multiple interactions increases reduction |
ISO |
resveratrol inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue] |
CTD |
PMID:29281794 |
|
NCBI chr13:34,148,642...34,172,448
Ensembl chr13:34,148,670...34,172,426
|
|
|
G |
Gpc1 |
glypican 1 |
decreases degradation |
EXP |
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one results in decreased degradation of GPC1 protein |
CTD |
PMID:21642435 |
|
NCBI chr 1:92,759,367...92,787,933
Ensembl chr 1:92,759,367...92,788,501
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to Silicon Dioxide] which results in increased secretion of IL1B protein] |
CTD |
PMID:36860548 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
|
G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A |
multiple interactions |
ISO |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to 1-(3-chlorophenyl)piperazine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine] |
CTD |
PMID:8539317 |
|
NCBI chr13:105,580,040...105,584,630
Ensembl chr13:105,580,147...105,584,630
|
|
|
G |
Bax |
BCL2-associated X protein |
increases response to substance |
ISO |
BAX protein results in increased susceptibility to Acridine Orange |
CTD |
PMID:16177561 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions |
ISO |
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA |
CTD |
PMID:16814760 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
Acridine Orange results in increased stability of and results in increased activity of TP53 protein |
CTD |
PMID:16177561 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Ambenonium Chloride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
App |
amyloid beta precursor protein |
affects cleavage |
ISO |
Ambenonium Chloride affects the cleavage of APP protein |
CTD |
PMID:11099780 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
|
G |
Slc19a3 |
solute carrier family 19, member 3 |
multiple interactions |
ISO |
Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] |
CTD |
PMID:26528626 |
|
NCBI chr 1:82,990,242...83,016,541
Ensembl chr 1:82,990,244...83,016,169
|
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
increases hydroxylation multiple interactions increases metabolic processing |
ISO |
CYP2D6 protein results in increased hydroxylation of Atomoxetine Hydrochloride Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride] |
CTD |
PMID:17470523 PMID:34431675 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
increases expression multiple interactions |
ISO |
Benzophenoneidum results in increased expression of ALDH1A1 protein ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:28722353 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Ano6 |
anoctamin 6 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ANO6 protein |
CTD |
PMID:28722353 |
|
NCBI chr15:95,688,724...95,873,353
Ensembl chr15:95,688,724...95,872,632
|
|
G |
Araf |
Araf proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ARAF protein |
CTD |
PMID:28722353 |
|
NCBI chr X:20,663,946...20,726,760
Ensembl chr X:20,664,053...20,726,758
|
|
G |
Atp6ap2 |
ATPase, H+ transporting, lysosomal accessory protein 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ATP6AP2 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:12,453,998...12,483,290
Ensembl chr X:12,454,040...12,483,288
|
|
G |
Ccdc22 |
coiled-coil domain containing 22 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC22 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:7,460,048...7,471,659
Ensembl chr X:7,460,048...7,471,756
|
|
G |
Ccdc39 |
coiled-coil domain containing 39 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC39 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:33,864,906...33,898,473
Ensembl chr 3:33,866,511...33,898,459
|
|
G |
Cd44 |
CD44 antigen |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CD44 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Chtf18 |
CTF18, chromosome transmission fidelity factor 18 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CHTF18 protein |
CTD |
PMID:28722353 |
|
NCBI chr17:25,938,004...25,946,409
Ensembl chr17:25,937,900...25,946,393
|
|
G |
Commd1 |
COMM domain containing 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COMMD1 protein |
CTD |
PMID:28722353 |
|
NCBI chr11:22,849,728...22,934,539
Ensembl chr11:22,846,136...22,932,382
|
|
G |
Cops7b |
COP9 signalosome subunit 7B |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COPS7B protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:86,510,363...86,534,550
Ensembl chr 1:86,510,626...86,537,097
|
|
G |
Cul3 |
cullin 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CUL3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:80,242,640...80,318,426
Ensembl chr 1:80,242,640...80,318,197
|
|
G |
Dynlt1b |
dynein light chain Tctex-type 1B |
increases expression |
ISO |
Benzophenoneidum results in increased expression of DYNLT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr17:6,697,511...6,703,695
Ensembl chr17:6,697,511...6,703,695
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of EIF4G3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 4:137,719,090...137,934,397
Ensembl chr 4:137,720,333...137,935,819
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of FASTKD2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:63,769,758...63,792,544
Ensembl chr 1:63,769,773...63,793,814
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Benzophenoneidum results in increased phosphorylation of H2AX protein |
CTD |
PMID:37527026 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hook3 |
hook microtubule tethering protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HOOK3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 8:26,511,449...26,609,646
Ensembl chr 8:26,511,449...26,609,252
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HSD17B7 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:169,777,109...169,796,757
Ensembl chr 1:169,777,104...169,796,810
|
|
G |
Htt |
huntingtin |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HTT protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:34,919,084...35,069,878
Ensembl chr 5:34,919,084...35,069,878
|
|
G |
Iqgap3 |
IQ motif containing GTPase activating protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of IQGAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:87,989,309...88,028,355
Ensembl chr 3:87,989,278...88,028,355
|
|
G |
Kifap3 |
kinesin-associated protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of KIFAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:163,589,711...163,744,676
Ensembl chr 1:163,607,152...163,744,678
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein |
CTD |
PMID:28722353 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map2k4 |
mitogen-activated protein kinase kinase 4 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MAP2K4 protein |
CTD |
PMID:28722353 |
|
NCBI chr11:65,579,070...65,679,185
Ensembl chr11:65,579,069...65,679,123
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MBD3 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:80,228,373...80,235,365
Ensembl chr10:80,228,373...80,235,384
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MKI67 protein |
CTD |
PMID:37527026 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Noa1 |
nitric oxide associated 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NOA1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:77,442,016...77,458,276
Ensembl chr 5:77,442,029...77,457,931
|
|
G |
Nup62 |
nucleoporin 62 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NUP62 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:44,465,512...44,481,260
Ensembl chr 7:44,465,512...44,480,236
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PLCG1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:160,573,230...160,617,680
Ensembl chr 2:160,573,220...160,617,680
|
|
G |
Ppp4r1 |
protein phosphatase 4, regulatory subunit 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PPP4R1 protein |
CTD |
PMID:28722353 |
|
NCBI chr17:66,089,253...66,148,921
Ensembl chr17:66,089,568...66,148,921
|
|
G |
Prim2 |
DNA primase, p58 subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRIM2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:33,492,889...33,708,867
Ensembl chr 1:33,492,891...33,708,876
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PROM1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:44,150,963...44,260,850
Ensembl chr 5:44,150,962...44,259,374
|
|
G |
Prorp |
protein only RNase P catalytic subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRORP protein |
CTD |
PMID:28722353 |
|
NCBI chr12:55,349,422...55,429,276
Ensembl chr12:55,346,362...55,429,318
|
|
G |
Shmt1 |
serine hydroxymethyltransferase 1 (soluble) |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SHMT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr11:60,679,723...60,702,062
Ensembl chr11:60,678,930...60,702,544
|
|
G |
Srsf11 |
serine and arginine-rich splicing factor 11 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SRSF11 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:157,716,552...157,742,304
Ensembl chr 3:157,716,110...157,742,276
|
|
G |
Tbc1d15 |
TBC1 domain family, member 15 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TBC1D15 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:115,031,459...115,087,343
Ensembl chr10:115,033,777...115,087,372
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TFAM protein |
CTD |
PMID:28722353 |
|
NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of USP24 protein |
CTD |
PMID:28722353 |
|
NCBI chr 4:106,173,179...106,303,798
Ensembl chr 4:106,173,417...106,298,519
|
|
G |
Washc5 |
WASH complex subunit 5 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of WASHC5 protein |
CTD |
PMID:28722353 |
|
NCBI chr15:59,203,712...59,246,043
Ensembl chr15:59,203,846...59,246,016
|
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
increases activity |
ISO |
Azure A results in increased activity of GPT protein |
CTD |
PMID:33775737 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[Azure B affects the cleavage of APP protein] which results in decreased secretion of APP protein modified form; Azure B results in decreased expression of and affects the cleavage of APP protein |
CTD |
PMID:30500345 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Bace1 |
beta-site APP cleaving enzyme 1 |
decreases activity |
ISO |
Azure B results in decreased activity of BACE1 protein |
CTD |
PMID:30500345 |
|
NCBI chr 9:45,749,878...45,775,694
Ensembl chr 9:45,749,878...45,775,697
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of AACS mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:125,552,937...125,594,469
Ensembl chr 5:125,552,878...125,594,474
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA1 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abca12 |
ATP-binding cassette, sub-family A member 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ABCA12 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 1:71,282,249...71,454,069
Ensembl chr 1:71,281,435...71,454,069
|
|
G |
Abca6 |
ATP-binding cassette, sub-family A member 6 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA6 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr11:110,065,464...110,142,811
Ensembl chr11:110,067,646...110,142,602
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ACOD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:103,284,448...103,294,009
Ensembl chr14:103,284,413...103,294,009
|
|
G |
Acp6 |
acid phosphatase 6, lysophosphatidic |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ACP6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:97,066,070...97,083,892
Ensembl chr 3:97,066,093...97,084,615
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ACSL4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531
|
|
G |
Ada |
adenosine deaminase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ADA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ADH1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ADORA1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:134,126,953...134,163,195
Ensembl chr 1:134,126,963...134,163,169
|
|
G |
Adra2a |
adrenergic receptor, alpha 2a |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403
|
|
G |
Akr1b10 |
aldo-keto reductase family 1, member B10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AKR1B10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885
|
|
G |
Alb |
albumin |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ALB mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AMIGO2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr15:97,141,955...97,145,168
Ensembl chr15:97,142,006...97,145,168
|
|
G |
Apoa1 |
apolipoprotein A-I |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of APOA1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apoa2 |
apolipoprotein A-II |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of APOA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948
|
|
G |
Apoc1 |
apolipoprotein C-I |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of APOC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:19,423,405...19,426,584
Ensembl chr 7:19,423,406...19,426,585
|
|
G |
Aqp3 |
aquaporin 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of AQP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Areg |
amphiregulin |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of AREG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Arg2 |
arginase type II |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ARG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ART3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:92,479,659...92,562,487
Ensembl chr 5:92,479,686...92,562,487
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATF4 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ATP5F1E mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:174,302,868...174,305,894
Ensembl chr 2:174,302,865...174,305,898
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ATP5MG mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 9:44,824,546...44,832,470
Ensembl chr 9:44,823,855...44,832,040
|
|
G |
B3galt4 |
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4 |
affects response to substance |
ISO |
B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,168,886...34,170,462
Ensembl chr17:34,168,883...34,170,462
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BAMBI mRNA |
CTD |
PMID:20146380 |
|
NCBI chr18:3,507,011...3,516,404
Ensembl chr18:3,507,923...3,516,404
|
|
G |
Bcl3 |
B cell leukemia/lymphoma 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of BCL3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695
|
|
G |
Btc |
betacellulin, epidermal growth factor family member |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of BTC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:91,505,120...91,550,853
Ensembl chr 5:91,505,120...91,550,853
|
|
G |
C1s2 |
complement component 1, s subcomponent 2 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:124,601,584...124,613,044
Ensembl chr 6:124,601,584...124,613,044
|
|
G |
C3 |
complement component 3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of CASP3 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:31982400 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CASP8 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CCL11 protein |
CTD |
PMID:30517752 |
|
NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
EXP ISO |
Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein Benzalkonium Compounds results in increased secretion of CCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31707104 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL20 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CCL24 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:135,598,789...135,601,977
Ensembl chr 5:135,598,791...135,601,903
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
EXP |
Benzalkonium Compounds results in increased expression of CCL3 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression multiple interactions increases expression |
ISO EXP |
Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein Benzalkonium Compounds results in increased expression of CCL4 protein |
CTD |
PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CCL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCN2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccn3 |
cellular communication network factor 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CCN3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:54,609,306...54,617,158
Ensembl chr15:54,609,098...54,617,435
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CCR4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:114,319,384...114,334,544
Ensembl chr 9:114,319,384...114,333,984
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CCR5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736
|
|
G |
Cd177 |
CD177 antigen |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:24,443,408...24,459,759
Ensembl chr 7:24,443,408...24,459,736
|
|
G |
Cd274 |
CD274 antigen |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495
|
|
G |
Cd300c2 |
CD300C molecule 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CD300C2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:114,887,595...114,892,706
Ensembl chr11:114,887,547...114,895,058
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression multiple interactions |
ISO |
Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein] |
CTD |
PMID:36725023 |
|
NCBI chr11:98,798,627...98,814,768
Ensembl chr11:98,798,627...98,814,766
|
|
G |
Cfap61 |
cilia and flagella associated protein 61 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CFAP61 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:145,776,677...146,056,955
Ensembl chr 2:145,776,704...146,056,959
|
|
G |
Cfd |
complement factor D |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CFD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:79,726,687...79,728,489
Ensembl chr10:79,726,687...79,728,489
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CHI3L1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919
|
|
G |
Chil3 |
chitinase-like 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CHIL3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:106,054,870...106,074,852
Ensembl chr 3:106,054,870...106,074,880
|
|
G |
Chrnb4 |
cholinergic receptor, nicotinic, beta polypeptide 4 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:54,935,438...54,956,236
Ensembl chr 9:54,935,438...54,956,063
|
|
G |
Cimap1d |
CIMAP1 family member D |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CIMAP1D mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:79,475,352...79,491,599
Ensembl chr10:79,475,360...79,481,572
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CLCF1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544
|
|
G |
Cnfn |
cornifelin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein |
CTD |
PMID:25377654 |
|
NCBI chr 7:25,067,041...25,069,149
Ensembl chr 7:25,067,045...25,069,149
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CSF1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CSF2 protein |
CTD |
PMID:30517752 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CSF3 protein |
CTD |
PMID:30517752 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Ctps1 |
cytidine 5'-triphosphate synthase 1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:120,397,065...120,427,473
Ensembl chr 4:120,397,065...120,427,473
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
EXP |
Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein |
CTD |
PMID:23445166 PMID:30517752 PMID:31158415 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
decreases expression increases expression increases secretion decreases secretion |
ISO |
Benzalkonium Compounds results in decreased expression of CXCL8 mRNA; Benzalkonium Compounds results in decreased expression of CXCL8 protein Benzalkonium Compounds results in increased expression of CXCL8 mRNA Benzalkonium Compounds results in increased secretion of CXCL8 protein Benzalkonium Compounds results in decreased secretion of CXCL8 protein |
CTD |
PMID:8006454 PMID:12781210 PMID:16099135 PMID:17763283 PMID:19729060 PMID:20146380 PMID:21920952 PMID:25290854 PMID:27965148 PMID:28214551 PMID:28236482 PMID:30806763 More...
|
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
EXP |
Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31158415 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcl5 |
C-X-C motif chemokine ligand 5 |
multiple interactions increases expression |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr 5:90,907,157...90,909,484
Ensembl chr 5:90,907,219...90,909,483
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 1:74,228,862...74,233,867
Ensembl chr 1:74,230,944...74,233,790
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR4 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA Benzalkonium Compounds results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20713136 PMID:30806763 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CYP51 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DDIT3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of DHCR24 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases activity increases expression |
ISO EXP |
Benzalkonium Compounds results in decreased activity of DHCR7 protein Benzalkonium Compounds results in increased expression of DHCR7 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dio1 |
deiodinase, iodothyronine, type I |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366
|
|
G |
Dio2 |
deiodinase, iodothyronine, type II |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812
|
|
G |
Dio3 |
deiodinase, iodothyronine type III |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of DLK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:109,418,411...109,429,262
Ensembl chr12:109,418,749...109,429,262
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DUSP1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DUSP10 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:183,766,575...183,807,833
Ensembl chr 1:183,745,499...183,807,833
|
|
G |
Ebp |
EBP cholestenol delta-isomerase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EBP mRNA |
CTD |
PMID:26919959 |
|
NCBI chr X:8,051,568...8,059,751
Ensembl chr X:8,051,568...8,059,751
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of EGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EGR1 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Elf3 |
E74-like factor 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ELF3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:135,181,312...135,186,210
Ensembl chr 1:135,181,313...135,186,306
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL1 mRNA |
CTD |
PMID:29155129 |
|
NCBI chr 4:118,285,321...118,290,150
Ensembl chr 4:118,285,290...118,290,150
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ELOVL6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:129,326,035...129,432,144
Ensembl chr 3:129,326,004...129,432,144
|
|
G |
Endou |
endonuclease, polyU-specific |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ENDOU mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:97,608,896...97,629,286
Ensembl chr15:97,608,896...97,629,220
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ENO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336 Ensembl chr18:150,321,178...150,333,336
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ETNK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:143,112,592...143,154,272
Ensembl chr 6:143,112,947...143,178,033
|
|
G |
Exo1 |
exonuclease 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of EXO1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:175,708,334...175,738,962
Ensembl chr 1:175,708,147...175,741,055
|
|
G |
Ezr |
ezrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein |
CTD |
PMID:29893927 |
|
NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183
|
|
G |
Fam83a |
family with sequence similarity 83, member A |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of FAM83A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:57,847,983...57,874,102
Ensembl chr15:57,848,815...57,874,405
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of FGR mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:132,701,406...132,729,204
Ensembl chr 4:132,701,406...132,729,221
|
|
G |
Flg |
filaggrin |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of FLG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:93,180,853...93,200,996
Ensembl chr 3:93,180,830...93,200,993
|
|
G |
Foxc1 |
forkhead box C1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:31,990,629...31,994,618
Ensembl chr13:31,990,616...31,996,459
|
|
G |
Foxn1 |
forkhead box N1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:78,248,403...78,277,597
Ensembl chr11:78,248,403...78,277,384
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLC mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLM mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gm15283 |
predicted gene 15283 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HIF1A-AS3 |
CTD |
PMID:37149095 |
|
NCBI chr12:73,981,498...73,999,213
Ensembl chr12:73,889,811...73,996,735
|
|
G |
Gm22140 |
predicted gene, 22140 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of RNU6-454P |
CTD |
PMID:37149095 |
|
NCBI chr 8:32,676,173...32,676,276
Ensembl chr 8:32,676,157...32,676,276
|
|
G |
Gm23442 |
predicted gene, 23442 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SNORA38 |
CTD |
PMID:37149095 |
|
NCBI chr17:35,381,539...35,381,672
Ensembl chr17:35,381,539...35,381,672
|
|
G |
Gm24411 |
predicted gene, 24411 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SNORA71D mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 2:158,198,344...158,198,474
Ensembl chr 2:158,198,344...158,198,474
|
|
G |
Gm25464 |
predicted gene, 25464 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of RNU6-643P |
CTD |
PMID:37149095 |
|
NCBI chr14:122,625,466...122,625,572
Ensembl chr14:122,625,466...122,625,572
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of GPX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gsdma3 |
gasdermin A3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:98,517,175...98,529,627
Ensembl chr11:98,517,186...98,529,052
|
|
G |
H2-Oa |
histocompatibility 2, O region alpha locus |
affects response to substance |
ISO |
HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208
|
|
G |
H2-Ob |
histocompatibility 2, O region beta locus |
affects response to substance |
ISO |
HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,457,879...34,464,882
Ensembl chr17:34,457,877...34,473,388
|
|
G |
H2-Pa |
histocompatibility 2, P region alpha locus |
affects response to substance |
ISO |
HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,303,587...34,304,826
Ensembl chr17:34,303,575...34,304,797
|
|
G |
Hamp2 |
hepcidin antimicrobial peptide 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of HAMP2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:30,621,797...30,623,606
Ensembl chr 7:30,621,797...30,624,106
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of HBEGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858
|
|
G |
Hck |
hemopoietic cell kinase |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:152,950,388...152,993,361
Ensembl chr 2:152,950,388...152,993,361
|
|
G |
Herpud1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HERPUD1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of HIF1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
increases expression |
ISO EXP |
Benzalkonium Compounds results in increased expression of HMGCR mRNA |
CTD |
PMID:26919959 PMID:31199489 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of HMGCS2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMOX1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hoxa7 |
homeobox A7 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of HOXA7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:52,191,471...52,198,757
Ensembl chr 6:52,191,471...52,198,834
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of HSD17B7 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:169,777,109...169,796,757
Ensembl chr 1:169,777,104...169,796,810
|
|
G |
Hspa5 |
heat shock protein 5 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HSPA5 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein |
CTD |
PMID:21742781 PMID:30806763 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ID1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IDI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487
|
|
G |
Ifna |
interferon alpha |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IFNA protein |
CTD |
PMID:30517752 |
|
|
|
G |
Ifng |
interferon gamma |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IFNG protein |
CTD |
PMID:30517752 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igha |
immunoglobulin heavy constant alpha |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:113,219,824...113,223,856
Ensembl chr12:113,218,450...113,223,856
|
|
G |
Ighg3 |
Immunoglobulin heavy constant gamma 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IGHG3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:113,321,062...113,324,852
Ensembl chr12:113,319,844...113,324,852
|
|
G |
Igll1 |
immunoglobulin lambda-like polypeptide 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of IGHD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:16,678,535...16,681,849
Ensembl chr16:16,678,535...16,681,849
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein Benzalkonium Compounds results in increased expression of IL10 protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il13ra2 |
interleukin 13 receptor, alpha 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL13RA2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:146,166,474...146,214,982
Ensembl chr X:146,166,472...146,212,188
|
|
G |
Il15 |
interleukin 15 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL15 protein |
CTD |
PMID:30517752 |
|
NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851
|
|
G |
Il17f |
interleukin 17F |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL17F mRNA |
CTD |
PMID:23445166 |
|
NCBI chr 1:20,847,370...20,855,498
Ensembl chr 1:20,847,370...20,860,841
|
|
G |
Il18 |
interleukin 18 |
increases expression |
EXP ISO |
Benzalkonium Compounds results in increased expression of IL18 protein Benzalkonium Compounds results in increased expression of IL18 mRNA |
CTD |
PMID:30517752 PMID:30806763 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression multiple interactions increases secretion |
ISO EXP |
Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein Benzalkonium Compounds results in increased secretion of IL1A protein |
CTD |
PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 PMID:31158415 More...
|
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO EXP |
Benzalkonium Compounds results in increased expression of IL1B protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1f10 |
interleukin 1 family, member 10 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:24,177,095...24,184,236
Ensembl chr 2:24,181,208...24,183,832
|
|
G |
Il22b |
interleukin 22B |
multiple interactions increases expression |
EXP |
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein Benzalkonium Compounds results in increased expression of IL22 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:118,125,534...118,130,943
Ensembl chr10:118,125,534...118,130,943
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL23A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL24 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191
|
|
G |
Il27 |
interleukin 27 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL27 protein |
CTD |
PMID:30517752 |
|
NCBI chr 7:126,188,181...126,194,197
Ensembl chr 7:126,188,182...126,194,113
|
|
G |
Il3 |
interleukin 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL3 protein |
CTD |
PMID:30517752 |
|
NCBI chr11:54,155,911...54,158,105
Ensembl chr11:54,156,129...54,158,103
|
|
G |
Il31 |
interleukin 31 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL31 protein |
CTD |
PMID:30517752 |
|
NCBI chr 5:123,618,215...123,620,686
Ensembl chr 5:123,618,220...123,627,552
|
|
G |
Il31ra |
interleukin 31 receptor A |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of IL31RA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:112,649,439...112,717,266
Ensembl chr13:112,656,432...112,730,894
|
|
G |
Il34 |
interleukin 34 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of IL34 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:111,467,809...111,532,579
Ensembl chr 8:111,468,461...111,532,556
|
|
G |
Il36a |
interleukin 36A |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL36A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:24,105,429...24,115,713
Ensembl chr 2:24,105,430...24,115,714
|
|
G |
Il36b |
interleukin 36B |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL36B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:24,043,184...24,050,115
Ensembl chr 2:24,043,173...24,050,531
|
|
G |
Il36g |
interleukin 36G |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL36G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:24,076,488...24,083,579
Ensembl chr 2:24,076,488...24,083,580
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
EXP |
Benzalkonium Compounds results in increased expression of IL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions increases expression affects response to substance |
ISO EXP |
Benzalkonium Compounds results in increased secretion of IL6 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein |
CTD |
PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 PMID:31158415 PMID:31707104 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il6ra |
interleukin 6 receptor, alpha |
increases response to substance multiple interactions |
EXP |
IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein |
CTD |
PMID:31158415 |
|
NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL7R mRNA |
CTD |
PMID:20713136 |
|
NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262
|
|
G |
Inhba |
inhibin beta-A |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of INHBA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:16,178,841...16,206,194
Ensembl chr13:16,186,436...16,206,206
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of INSIG1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
|
|
G |
Isl1 |
ISL1 transcription factor, LIM/homeodomain |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ISL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:116,434,806...116,446,224
Ensembl chr13:116,434,817...116,446,225
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kdm7a |
lysine (K)-specific demethylase 7A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KDM7A mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 6:39,113,554...39,183,707
Ensembl chr 6:39,113,557...39,183,723
|
|
G |
Kdm8 |
lysine (K)-specific demethylase 8 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of KDM8 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:125,043,788...125,062,823
Ensembl chr 7:125,043,848...125,061,441
|
|
G |
Klf2 |
Kruppel-like transcription factor 2 (lung) |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KLF2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of KLK8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:43,447,001...43,453,250
Ensembl chr 7:43,447,001...43,453,250
|
|
G |
Krt2 |
keratin 2 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:101,719,124...101,727,391
Ensembl chr15:101,719,124...101,726,604
|
|
G |
Krt6b |
keratin 6B |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of KRT6B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:101,584,458...101,588,728
Ensembl chr15:101,584,458...101,588,722
|
|
G |
Krtap14 |
keratin associated protein 14 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:88,622,179...88,623,033
Ensembl chr16:88,622,178...88,623,033
|
|
G |
Krtap16-3 |
keratin associated protein 16-3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:88,759,192...88,759,761
Ensembl chr16:88,759,161...88,759,761
|
|
G |
Krtap19-5 |
keratin associated protein 19-5 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:88,692,856...88,693,337
Ensembl chr16:88,692,856...88,693,345
|
|
G |
Krtap19-9b |
keratin associated protein 19-9B |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:88,728,692...88,729,152
Ensembl chr16:88,728,692...88,729,153
|
|
G |
Krtap6-1 |
keratin associated protein 6-1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:88,828,587...88,829,180
Ensembl chr16:88,828,587...88,829,180
|
|
G |
Krtap6-6 |
keratin associated protein 6-6 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:88,860,297...88,860,890
Ensembl chr16:88,860,300...88,860,890
|
|
G |
Lce1g |
late cornified envelope 1G |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of LCE1G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,657,458...92,659,645
Ensembl chr 3:92,657,455...92,659,645
|
|
G |
Lce1m |
late cornified envelope 1M |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of LCE1M mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,925,114...92,926,368
Ensembl chr 3:92,925,117...92,926,367
|
|
G |
Lce3c |
late cornified envelope 3C |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of LCE3C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,851,793...92,853,038
Ensembl chr 3:92,851,793...92,853,040
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of LDHA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of LDLR mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lif |
leukemia inhibitory factor |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of LIF protein |
CTD |
PMID:30517752 |
|
NCBI chr11:4,207,587...4,222,514
Ensembl chr11:4,207,557...4,222,514
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of LOXL1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 9:58,195,006...58,220,495
Ensembl chr 9:58,195,021...58,220,469
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of LST1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:35,404,071...35,407,416
Ensembl chr17:35,404,071...35,407,415
|
|
G |
Ltb |
lymphotoxin B |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
increases phosphorylation |
ISO |
Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:15737199 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mesp2 |
mesoderm posterior 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of MESP2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:79,460,475...79,463,179
Ensembl chr 7:79,460,475...79,463,187
|
|
G |
Mif |
macrophage migration inhibitory factor (glycosylation-inhibiting factor) |
increases secretion |
ISO |
Benzalkonium Compounds results in increased secretion of MIF protein |
CTD |
PMID:31707104 |
|
NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:7,502,343...7,510,243
Ensembl chr 9:7,502,353...7,510,241
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MMP12 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:7,344,397...7,360,461
Ensembl chr 9:7,344,381...7,369,499
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity |
ISO |
Benzalkonium Compounds results in increased activity of MMP2 protein |
CTD |
PMID:21058936 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:23,847,289...23,864,006
Ensembl chr17:23,847,285...23,864,251
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity |
EXP ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA Benzalkonium Compounds results in increased activity of MMP9 protein |
CTD |
PMID:21058936 PMID:30171875 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mrgpra2b |
MAS-related GPR, member A2B |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:47,113,555...47,139,330
Ensembl chr 7:47,113,554...47,178,610
|
|
G |
Msmo1 |
methylsterol monoxygenase 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MSMO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:65,171,157...65,186,822
Ensembl chr 8:65,171,173...65,186,826
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:53,620,917...53,626,816
Ensembl chr13:53,620,920...53,627,110
|
|
G |
Mt2 |
metallothionein 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of MT2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:86,050,933...86,112,969
Ensembl chr 8:86,050,932...86,112,974
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:11,900,371...11,907,449
Ensembl chr 6:11,900,291...11,907,496
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of NR4A2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 2:56,996,845...57,014,152
Ensembl chr 2:56,996,842...57,014,015
|
|
G |
Nrg2 |
neuregulin 2 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:36,147,634...36,332,754
Ensembl chr18:36,150,705...36,330,433
|
|
G |
Ntrk3 |
neurotrophic tyrosine kinase, receptor, type 3 |
affects response to substance |
ISO |
NTRK3 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 7:77,825,711...78,228,865
Ensembl chr 7:77,825,707...78,387,760
|
|
G |
Ocln |
occludin |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of OCLN protein |
CTD |
PMID:29514330 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ODC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
Olr1 |
oxidized low density lipoprotein (lectin-like) receptor 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of OLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128
|
|
G |
Orm1 |
orosomucoid 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ORM1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:63,262,793...63,266,400
Ensembl chr 4:63,262,797...63,266,400
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases cleavage |
ISO |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein] |
CTD |
PMID:31982400 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pbk |
PDZ binding kinase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PBK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:66,043,337...66,055,271
Ensembl chr14:66,043,286...66,055,271
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of PCSK9 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:106,299,531...106,321,522
Ensembl chr 4:106,299,526...106,321,526
|
|
G |
Pdcd1 |
programmed cell death 1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:93,966,027...93,980,278
Ensembl chr 1:93,966,027...93,980,278
|
|
G |
Pfdn6 |
prefoldin subunit 6 |
affects response to substance |
ISO |
PFDN6 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,157,883...34,159,317
Ensembl chr17:34,157,795...34,159,317
|
|
G |
Pglyrp3 |
peptidoglycan recognition protein 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:91,919,784...91,939,979
Ensembl chr 3:91,921,890...91,938,889
|
|
G |
Pgp |
phosphoglycolate phosphatase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PGP mRNA |
CTD |
PMID:31199489 |
|
NCBI chr17:24,689,400...24,692,084
Ensembl chr17:24,689,366...24,692,084
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:138,526,558...138,590,784
Ensembl chr 4:138,526,555...138,590,793
|
|
G |
Plcxd3 |
phosphatidylinositol-specific phospholipase C, X domain containing 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PLCXD3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr15:4,404,973...4,605,067
Ensembl chr15:4,404,973...4,605,035
|
|
G |
Plk2 |
polo like kinase 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PLK2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656
|
|
G |
Polr1d |
polymerase (RNA) I polypeptide D |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of POLR1D mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:147,013,525...147,048,171
Ensembl chr 5:147,013,860...147,048,407
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of PPARA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Prkaa2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PRKAA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087
|
|
G |
Prkag2 |
protein kinase, AMP-activated, gamma 2 non-catalytic subunit |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PRKAG2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:25,067,733...25,311,576
Ensembl chr 5:25,067,742...25,305,640
|
|
G |
Prokr2 |
prokineticin receptor 2 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:132,211,625...132,227,413
Ensembl chr 2:132,179,653...132,227,367
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PTGS2 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptx3 |
pentraxin related gene |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:66,127,308...66,133,227
Ensembl chr 3:66,127,331...66,133,226
|
|
G |
Reg1 |
regenerating islet-derived 1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:78,402,966...78,405,651
Ensembl chr 6:78,399,694...78,405,650
|
|
G |
Reg3g |
regenerating islet-derived 3 gamma |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855
|
|
G |
Rgl2 |
ral guanine nucleotide dissociation stimulator-like 2 |
affects response to substance |
ISO |
RGL2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,148,813...34,156,661
Ensembl chr17:34,148,517...34,156,661
|
|
G |
Rps18 |
ribosomal protein S18 |
affects response to substance |
ISO |
RPS18 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,170,972...34,174,639
Ensembl chr17:34,170,973...34,174,975
|
|
G |
Ryr1 |
ryanodine receptor 1, skeletal muscle |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:28,702,765...28,824,599
Ensembl chr 7:28,702,769...28,824,604
|
|
G |
Saa3 |
serum amyloid A 3 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:46,361,422...46,365,100
Ensembl chr 7:46,361,422...46,365,124
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of SCD1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SCD mRNA |
CTD |
PMID:29155129 |
|
NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303
|
|
G |
Serpinb13 |
serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 13 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:106,908,714...106,928,925
Ensembl chr 1:106,908,714...106,928,925
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SERPINE1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of SESN2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Sfn |
stratifin |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SFN mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479
|
|
G |
Sfrp4 |
secreted frizzled-related protein 4 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of SFRP4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:19,807,345...19,816,995
Ensembl chr13:19,807,274...19,817,164
|
|
G |
Siglece |
sialic acid binding Ig-like lectin E |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:43,300,494...43,309,585
Ensembl chr 7:43,300,494...43,309,585
|
|
G |
Skint7 |
selection and upkeep of intraepithelial T cells 7 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of SKINT7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:111,830,121...111,845,457
Ensembl chr 4:111,830,120...111,845,420
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SLC16A1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC7A11 mRNA |
CTD |
PMID:30806763 PMID:37149095 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Sox21 |
SRY (sex determining region Y)-box 21 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:118,470,645...118,474,442
Ensembl chr14:118,470,644...118,474,442
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,391,261...92,393,188
Ensembl chr 3:92,391,259...92,393,202
|
|
G |
Sprr1b |
small proline-rich protein 1B |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR1B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,344,115...92,346,124
Ensembl chr 3:92,344,116...92,346,096
|
|
G |
Sprr2a1 |
small proline-rich protein 2A1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR2A1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,123,142...92,129,798
Ensembl chr 3:92,123,106...92,129,218
|
|
G |
Sprr2a3 |
small proline-rich protein 2A3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR2A3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,192,611...92,196,571
Ensembl chr 3:92,192,724...92,198,712
|
|
G |
Sprr2b |
small proline-rich protein 2B |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,224,012...92,225,448
Ensembl chr 3:92,223,927...92,225,392
|
|
G |
Sprr2f |
small proline-rich protein 2F |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR2F mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,272,494...92,273,754
Ensembl chr 3:92,272,494...92,273,749
|
|
G |
Sprr2h |
small proline-rich protein 2H |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR2H mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,292,992...92,294,631
Ensembl chr 3:92,292,992...92,294,631
|
|
G |
Sprr2i |
small proline-rich protein 2I |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SPRR2I mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:92,315,298...92,316,577
Ensembl chr 3:92,315,298...92,316,578
|
|
G |
Sqle |
squalene epoxidase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SQLE mRNA |
CTD |
PMID:31199489 |
|
NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SREBF2 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Srms |
src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:180,847,356...180,854,964
Ensembl chr 2:180,847,355...180,854,978
|
|
G |
St14 |
suppression of tumorigenicity 14 (colon carcinoma) |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:30,999,886...31,043,138
Ensembl chr 9:31,000,698...31,043,149
|
|
G |
Tapbp |
TAP binding protein |
affects response to substance |
ISO |
TAPBP SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,138,452...34,148,264
Ensembl chr17:34,134,873...34,148,266
|
|
G |
Tfap2b |
transcription factor AP-2 beta |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:19,279,132...19,309,071
Ensembl chr 1:19,279,138...19,308,800
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TGFB1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgm3 |
transglutaminase 3, E polypeptide |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TGM3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:129,829,700...129,890,814
Ensembl chr 2:129,854,269...129,892,319
|
|
G |
Tgm7 |
transglutaminase 7 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of TGM7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:120,923,979...120,946,877
Ensembl chr 2:120,924,046...120,946,877
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of THBS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:65,082,023...65,090,945
Ensembl chr 5:65,082,022...65,090,906
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases activity |
EXP |
Benzalkonium Compounds results in increased activity of TLR4 protein |
CTD |
PMID:29514330 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tmprss11b |
transmembrane protease, serine 11B |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:86,806,326...86,824,221
Ensembl chr 5:86,805,490...86,824,221
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion increases expression |
ISO EXP |
Benzalkonium Compounds results in decreased secretion of TNF protein Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein |
CTD |
PMID:29953848 PMID:30171875 PMID:30517752 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip6 |
tumor necrosis factor alpha induced protein 6 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698
|
|
G |
Tnfrsf13c |
tumor necrosis factor receptor superfamily, member 13c |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:82,105,943...82,108,581
Ensembl chr15:82,105,944...82,108,570
|
|
G |
Tnfrsf26 |
tumor necrosis factor receptor superfamily, member 26 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:143,161,422...143,181,690
Ensembl chr 7:143,161,396...143,182,459
|
|
G |
Tnfrsf9 |
tumor necrosis factor receptor superfamily, member 9 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:151,004,612...151,030,561
Ensembl chr 4:150,999,019...151,030,559
|
|
G |
Tnfsf8 |
tumor necrosis factor (ligand) superfamily, member 8 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of TPI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259
|
|
G |
Trdc |
T cell receptor delta, constant region |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of TRDC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:54,380,308...54,383,565
Ensembl chr14:54,380,308...54,386,325
|
|
G |
Trdv4 |
T cell receptor delta variable 4 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of TRDV4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:54,312,461...54,312,972
Ensembl chr14:54,312,362...54,312,972
|
|
G |
Trem2 |
triggering receptor expressed on myeloid cells 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TREM2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:48,653,429...48,659,304
Ensembl chr17:48,653,429...48,661,175
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TRIB3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952
|
|
G |
Trp53 |
transformation related protein 53 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TP53 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850
|
|
G |
Ulbp1 |
UL16 binding protein 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ULBP1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr10:7,394,873...7,423,643
Ensembl chr10:7,390,362...7,423,638
|
|
G |
Upk3b |
uroplakin 3B |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of UPK3B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:136,067,350...136,073,847
Ensembl chr 5:136,067,350...136,075,341
|
|
G |
Uqcrq |
ubiquinol-cytochrome c reductase, complex III subunit VII |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of UQCRQ mRNA |
CTD |
PMID:31199489 |
|
NCBI chr11:53,318,749...53,321,658
Ensembl chr11:53,318,749...53,321,658
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of VEGFD mRNA |
CTD |
PMID:20146380 |
|
NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646
|
|
G |
Vtcn1 |
V-set domain containing T cell activation inhibitor 1 |
multiple interactions |
EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:100,732,775...100,805,555
Ensembl chr 3:100,732,775...100,804,238
|
|
G |
Wdr46 |
WD repeat domain 46 |
affects response to substance |
ISO |
WDR46 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr17:34,159,608...34,168,669
Ensembl chr17:34,159,634...34,168,671
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form |
CTD |
PMID:28236482 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Xcl1 |
chemokine (C motif) ligand 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of XCL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:164,759,216...164,763,094
Ensembl chr 1:164,759,213...164,763,096
|
|
|
G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
multiple interactions |
ISO |
Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375
|
|
|
G |
Abcd1 |
ATP-binding cassette, sub-family D member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ABCD1 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:72,760,203...72,782,140
Ensembl chr X:72,760,203...72,782,140
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of ADARB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:77,126,561...77,254,125
Ensembl chr10:77,126,560...77,254,104
|
|
G |
Agtrap |
angiotensin II, type I receptor-associated protein |
increases expression |
ISO |
Chlormequat results in increased expression of AGTRAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:148,161,518...148,172,521
Ensembl chr 4:148,161,518...148,172,488
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions |
ISO |
Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Alg12 |
ALG12 alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Chlormequat results in decreased expression of ALG12 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:88,689,448...88,703,498
Ensembl chr15:88,689,447...88,703,521
|
|
G |
Alg14 |
asparagine-linked glycosylation 14 |
decreases expression |
ISO |
Chlormequat results in decreased expression of ALG14 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:121,085,361...121,156,745
Ensembl chr 3:121,085,422...121,156,743
|
|
G |
Apol9a |
apolipoprotein L 9a |
increases expression |
ISO |
Chlormequat results in increased expression of APOL9A protein |
CTD |
PMID:34958886 |
|
NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
increases expression |
ISO |
Chlormequat results in increased expression of ARHGAP20 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:51,676,651...51,765,158
Ensembl chr 9:51,676,637...51,765,156
|
|
G |
Atl1 |
atlastin GTPase 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ATL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:69,939,879...70,010,859
Ensembl chr12:69,939,388...70,013,191
|
|
G |
Atp10b |
ATPase, class V, type 10B |
increases expression |
ISO |
Chlormequat results in increased expression of ATP10B protein |
CTD |
PMID:34958886 |
|
NCBI chr11:42,902,991...43,153,112
Ensembl chr11:43,040,704...43,153,112
|
|
G |
B9d2 |
B9 protein domain 2 |
increases expression |
ISO |
Chlormequat results in increased expression of B9D2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:25,380,205...25,385,987
Ensembl chr 7:25,380,205...25,385,983
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein like |
increases expression |
ISO |
Chlormequat results in increased expression of BET1L protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:140,433,297...140,437,306
Ensembl chr 7:140,433,307...140,437,490
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
decreases expression |
ISO |
Chlormequat results in decreased expression of BGLAP protein |
CTD |
PMID:28214531 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
C1qc |
complement component 1, q subcomponent, C chain |
increases expression |
ISO |
Chlormequat results in increased expression of C1QC protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of CAAP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:94,388,318...94,445,033
Ensembl chr 4:94,388,318...94,445,033
|
|
G |
Cbx1 |
chromobox 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CBX1 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:96,679,506...96,699,808
Ensembl chr11:96,679,953...96,699,466
|
|
G |
Ccdc32 |
coiled-coil domain containing 32 |
increases expression |
ISO |
Chlormequat results in increased expression of CCDC32 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:118,848,260...118,859,887
Ensembl chr 2:118,848,260...118,859,874
|
|
G |
Ccnyl1 |
cyclin Y-like 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CCNYL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:64,729,963...64,764,805
Ensembl chr 1:64,729,614...64,764,803
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
Chlormequat results in increased expression of CCS protein |
CTD |
PMID:34958886 |
|
NCBI chr19:4,875,394...4,889,326
Ensembl chr19:4,875,394...4,889,360
|
|
G |
Cd151 |
CD151 antigen |
decreases expression |
ISO |
Chlormequat results in decreased expression of CD151 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386
|
|
G |
Cd55 |
CD55 molecule, decay accelerating factor for complement |
increases expression |
ISO |
Chlormequat results in increased expression of CD55 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481
|
|
G |
Cfap298 |
cilia and flagella associate protien 298 |
increases expression |
ISO |
Chlormequat results in increased expression of CFAP298 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:90,721,178...90,731,737
Ensembl chr16:90,722,697...90,732,002
|
|
G |
Chmp7 |
charged multivesicular body protein 7 |
increases expression |
ISO |
Chlormequat results in increased expression of CHMP7 protein |
CTD |
PMID:34958886 |
|
NCBI chr14:69,954,428...69,970,019
Ensembl chr14:69,954,449...69,969,990
|
|
G |
Coprs |
coordinator of PRMT5, differentiation stimulator |
increases expression |
ISO |
Chlormequat results in increased expression of COPRS protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:13,934,787...13,940,501
Ensembl chr 8:13,934,794...13,940,281
|
|
G |
Coq4 |
coenzyme Q4 |
increases expression |
ISO |
Chlormequat results in increased expression of COQ4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:29,677,505...29,687,947
Ensembl chr 2:29,677,505...29,687,947
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation |
ISO |
Chlormequat results in increased phosphorylation of CREB1 protein |
CTD |
PMID:38552810 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CSNK1A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr18:61,687,307...61,723,391
Ensembl chr18:61,688,345...61,723,132
|
|
G |
Ctss |
cathepsin S |
decreases expression |
ISO |
Chlormequat results in decreased expression of CTSS protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of CYP11A1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Dap |
death-associated protein |
decreases expression |
ISO |
Chlormequat results in decreased expression of DAP protein |
CTD |
PMID:34958886 |
|
NCBI chr15:31,224,531...31,274,484
Ensembl chr15:31,224,460...31,274,487
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
increases expression |
ISO |
Chlormequat results in increased expression of DCAF13 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:38,976,300...39,010,251
Ensembl chr15:38,976,260...39,010,251
|
|
G |
Dctn6 |
dynactin 6 |
increases expression |
ISO |
Chlormequat results in increased expression of DCTN6 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:34,557,574...34,575,866
Ensembl chr 8:34,557,574...34,575,950
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of DDIT3 protein] |
CTD |
PMID:34958886 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Degs1 |
delta 4-desaturase, sphingolipid 1 |
increases expression |
ISO |
Chlormequat results in increased expression of DEGS1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:182,103,529...182,110,366
Ensembl chr 1:182,103,337...182,110,369
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
increases expression |
ISO |
Chlormequat results in increased expression of DNAJC14 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:128,641,423...128,655,317
Ensembl chr10:128,639,931...128,655,315
|
|
G |
Dnmbp |
dynamin binding protein |
increases expression |
ISO |
Chlormequat results in increased expression of DNMBP protein |
CTD |
PMID:34958886 |
|
NCBI chr19:43,835,259...43,930,930
Ensembl chr19:43,835,260...43,928,630
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
increases expression |
ISO |
Chlormequat results in increased expression of DYNLT3 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:9,520,509...9,529,222
Ensembl chr X:9,520,506...9,529,242
|
|
G |
Ears2 |
glutamyl-tRNA synthetase 2, mitochondrial |
increases expression |
ISO |
Chlormequat results in increased expression of EARS2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:121,633,385...121,666,436
Ensembl chr 7:121,636,436...121,666,486
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of EEF1A2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:180,783,551...180,798,808
Ensembl chr 2:180,789,446...180,798,807
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ELOVL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:118,285,321...118,290,150
Ensembl chr 4:118,285,290...118,290,150
|
|
G |
Elovl5 |
ELOVL fatty acid elongase 5 |
increases expression |
ISO |
Chlormequat results in increased expression of ELOVL5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:77,824,647...77,891,801
Ensembl chr 9:77,824,646...77,891,801
|
|
G |
Eno3 |
enolase 3, beta muscle |
decreases expression |
ISO |
Chlormequat results in decreased expression of ENO3 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339
|
|
G |
Evc |
EvC ciliary complex subunit 1 |
increases expression |
ISO |
Chlormequat results in increased expression of EVC protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:37,446,314...37,495,489
Ensembl chr 5:37,446,442...37,494,238
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
decreases expression |
ISO |
Chlormequat results in decreased expression of FABP4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fancd2 |
Fanconi anemia, complementation group D2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of FANCD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:113,508,622...113,573,981
Ensembl chr 6:113,508,643...113,573,978
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Chlormequat results in increased expression of FBLN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:85,090,150...85,170,495
Ensembl chr15:85,090,150...85,170,736
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
decreases expression |
ISO |
Chlormequat results in decreased expression of FOS protein |
CTD |
PMID:34958886 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Foxk2 |
forkhead box K2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of FOXK2 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:121,150,805...121,200,726
Ensembl chr11:121,150,816...121,200,722
|
|
G |
Gabarap |
gamma-aminobutyric acid receptor associated protein |
increases expression |
ISO |
Chlormequat results in increased expression of GABARAP protein |
CTD |
PMID:34958886 |
|
NCBI chr11:69,882,196...69,885,775
Ensembl chr11:69,881,969...69,885,777
|
|
G |
Gh |
growth hormone |
increases expression |
ISO |
Chlormequat results in increased expression of GH1 protein |
CTD |
PMID:31704167 PMID:32622971 PMID:38552810 |
|
NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691
|
|
G |
Ghr |
growth hormone receptor |
decreases expression |
ISO |
Chlormequat results in decreased expression of GHR mRNA |
CTD |
PMID:28214531 |
|
NCBI chr15:3,347,237...3,612,834
Ensembl chr15:3,347,242...3,612,974
|
|
G |
Ghrh |
growth hormone releasing hormone |
increases expression |
ISO |
Chlormequat results in increased expression of GHRH protein |
CTD |
PMID:32622971 PMID:38552810 |
|
NCBI chr 2:157,171,416...157,190,645
Ensembl chr 2:157,171,417...157,189,426
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
increases expression |
ISO |
Chlormequat results in increased expression of GNAI1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353
|
|
G |
Gng5 |
G protein subunit gamma 5 |
decreases expression |
ISO |
Chlormequat results in decreased expression of GNG5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
increases expression |
ISO |
Chlormequat results in increased expression of GNRH1 protein |
CTD |
PMID:29447956 |
|
NCBI chr14:67,982,717...67,986,889
Ensembl chr14:67,982,630...67,986,888
|
|
G |
Gsta2 |
glutathione S-transferase, alpha 2 (Yc2) |
increases expression |
ISO |
Chlormequat results in increased expression of GSTA2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070
|
|
G |
Gtf2h5 |
general transcription factor IIH, polypeptide 5 |
increases expression |
ISO |
Chlormequat results in increased expression of GTF2H5 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:6,130,103...6,135,763
Ensembl chr17:6,130,061...6,136,792
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
ISO |
Chlormequat results in increased expression of H1-0 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:78,912,412...78,914,704
Ensembl chr15:78,912,650...78,914,704
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
increases expression |
ISO |
Chlormequat results in increased expression of H1-5 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:21,964,002...21,964,795
Ensembl chr13:21,964,053...21,964,795
|
|
G |
Hebp2 |
heme binding protein 2 |
increases expression |
ISO |
Chlormequat results in increased expression of HEBP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:18,415,871...18,421,824
Ensembl chr10:18,415,246...18,421,824
|
|
G |
Herpud2 |
HERPUD family member 2 |
increases expression |
ISO |
Chlormequat results in increased expression of HERPUD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:25,012,412...25,063,109
Ensembl chr 9:25,019,428...25,063,116
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
increases expression |
ISO |
Chlormequat results in increased expression of HNRNPC protein |
CTD |
PMID:34958886 |
|
NCBI chr14:52,310,834...52,341,462
Ensembl chr14:52,310,834...52,341,485
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of HSD3B1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression multiple interactions |
ISO |
Chlormequat results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of HSPA5 protein] |
CTD |
PMID:34958886 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression increases expression |
ISO |
Chlormequat affects the expression of IGF1 protein Chlormequat results in increased expression of IGF1 protein |
CTD |
PMID:28214531 PMID:31704167 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
decreases expression |
ISO |
Chlormequat results in decreased expression of INA protein |
CTD |
PMID:34958886 |
|
NCBI chr19:47,003,120...47,013,766
Ensembl chr19:47,003,137...47,013,766
|
|
G |
Itgb1bp1 |
integrin beta 1 binding protein 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ITGB1BP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:21,317,247...21,336,285
Ensembl chr12:21,290,826...21,336,285
|
|
G |
Kazn |
kazrin, periplakin interacting protein |
increases expression |
ISO |
Chlormequat results in increased expression of KAZN protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:141,829,701...142,801,231
Ensembl chr 4:141,829,701...142,205,056
|
|
G |
Klhl26 |
kelch-like 26 |
decreases expression |
ISO |
Chlormequat results in decreased expression of KLHL26 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:70,902,868...70,929,660
Ensembl chr 8:70,902,869...70,929,618
|
|
G |
Klhl7 |
kelch-like 7 |
decreases expression |
ISO |
Chlormequat results in decreased expression of KLHL7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:24,305,563...24,368,363
Ensembl chr 5:24,305,603...24,365,790
|
|
G |
Ldb1 |
LIM domain binding 1 |
increases expression |
ISO |
Chlormequat results in increased expression of LDB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:46,019,963...46,036,584
Ensembl chr19:46,020,009...46,033,653
|
|
G |
Lhb |
luteinizing hormone beta |
increases expression |
ISO |
Chlormequat results in increased expression of LHB protein |
CTD |
PMID:29447956 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lrrc7 |
leucine rich repeat containing 7 |
increases expression |
ISO |
Chlormequat results in increased expression of LRRC7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:157,772,823...158,268,254
Ensembl chr 3:157,788,528...158,267,858 Ensembl chr 3:157,788,528...158,267,858
|
|
G |
Macroh2a1 |
macroH2A.1 histone |
increases expression |
ISO |
Chlormequat results in increased expression of MACROH2A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:56,221,435...56,283,439
Ensembl chr13:56,221,432...56,284,174
|
|
G |
Macroh2a2 |
macroH2A.2 histone |
increases expression |
ISO |
Chlormequat results in increased expression of MACROH2A2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:61,574,419...61,620,383
Ensembl chr10:61,574,444...61,619,926
|
|
G |
Map4 |
microtubule-associated protein 4 |
decreases expression |
ISO |
Chlormequat results in decreased expression of MAP4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:109,758,909...109,913,018
Ensembl chr 9:109,760,528...109,913,023
|
|
G |
Mgat4b |
mannoside acetylglucosaminyltransferase 4, isoenzyme B |
increases expression |
ISO |
Chlormequat results in increased expression of MGAT4B protein |
CTD |
PMID:34958886 |
|
NCBI chr11:50,116,162...50,125,930
Ensembl chr11:50,101,717...50,125,930
|
|
G |
Mospd3 |
motile sperm domain containing 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of MOSPD3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:137,594,907...137,599,342
Ensembl chr 5:137,594,907...137,599,320
|
|
G |
Mov10 |
Mov10 RISC complex RNA helicase |
increases expression |
ISO |
Chlormequat results in increased expression of MOV10 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:104,702,144...104,725,935
Ensembl chr 3:104,702,152...104,725,879
|
|
G |
Mpp2 |
membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) |
decreases expression |
ISO |
Chlormequat results in decreased expression of MPP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:101,947,841...101,979,464
Ensembl chr11:101,947,841...101,979,341
|
|
G |
Mpv17l2 |
MPV17 mitochondrial membrane protein-like 2 |
increases expression |
ISO |
Chlormequat results in increased expression of MPV17L2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:71,211,295...71,213,589
Ensembl chr 8:71,211,295...71,213,592
|
|
G |
Mrpl51 |
mitochondrial ribosomal protein L51 |
increases expression |
ISO |
Chlormequat results in increased expression of MRPL51 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:125,169,163...125,171,355
Ensembl chr 6:125,168,764...125,173,232
|
|
G |
Mrpl54 |
mitochondrial ribosomal protein L54 |
increases expression |
ISO |
Chlormequat results in increased expression of MRPL54 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:81,100,556...81,102,760
Ensembl chr10:81,100,547...81,102,768
|
|
G |
Mrps14 |
mitochondrial ribosomal protein S14 |
increases expression |
ISO |
Chlormequat results in increased expression of MRPS14 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:160,022,785...160,028,756
Ensembl chr 1:160,022,785...160,029,740
|
|
G |
Mtrfr |
mitochondrial translation release factor in rescue |
increases expression |
ISO |
Chlormequat results in increased expression of MTRFR protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:124,466,152...124,479,915
Ensembl chr 5:124,466,152...124,479,907
|
|
G |
Ncl |
nucleolin |
increases expression |
ISO |
Chlormequat results in increased expression of NCL protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:86,272,441...86,287,177
Ensembl chr 1:86,272,441...86,287,122
|
|
G |
Nipa1 |
non imprinted in Prader-Willi/Angelman syndrome 1 homolog (human) |
decreases expression |
ISO |
Chlormequat results in decreased expression of NIPA1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:55,628,232...55,669,348
Ensembl chr 7:55,627,315...55,669,702
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of NPR3 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:11,839,982...11,907,287
Ensembl chr15:11,839,982...11,907,373
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
increases expression |
ISO |
Chlormequat results in increased expression of NR3C2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ORAI1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:123,153,078...123,168,515
Ensembl chr 5:123,153,137...123,168,519
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
increases expression |
ISO |
Chlormequat results in increased expression of PABPC1 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:36,595,902...36,609,825
Ensembl chr15:36,595,905...36,609,912
|
|
G |
Pabpc4 |
poly(A) binding protein, cytoplasmic 4 |
increases expression |
ISO |
Chlormequat results in increased expression of PABPC4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:123,172,722...123,192,718
Ensembl chr 4:123,156,144...123,192,718
|
|
G |
Pccb |
propionyl Coenzyme A carboxylase, beta polypeptide |
increases expression |
ISO |
Chlormequat results in increased expression of PCCB protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:100,864,085...100,916,993
Ensembl chr 9:100,864,085...100,916,951
|
|
G |
Pex26 |
peroxisomal biogenesis factor 26 |
increases expression |
ISO |
Chlormequat results in increased expression of PEX26 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:121,160,176...121,175,796
Ensembl chr 6:121,160,626...121,175,796
|
|
G |
Pgpep1 |
pyroglutamyl-peptidase I |
increases expression |
ISO |
Chlormequat results in increased expression of PGPEP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:71,099,086...71,113,096
Ensembl chr 8:71,099,085...71,113,038
|
|
G |
Phldb1 |
pleckstrin homology like domain, family B, member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of PHLDB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:44,597,605...44,649,800
Ensembl chr 9:44,597,601...44,646,495
|
|
G |
Pias3 |
protein inhibitor of activated STAT 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of PIAS3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:96,603,679...96,613,386
Ensembl chr 3:96,603,700...96,613,386
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
increases expression |
ISO |
Chlormequat results in increased expression of PIK3CD protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:149,733,625...149,787,023
Ensembl chr 4:149,733,625...149,787,028
|
|
G |
Pitpnm2 |
phosphatidylinositol transfer protein, membrane-associated 2 |
increases expression |
ISO |
Chlormequat results in increased expression of PITPNM2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:124,256,753...124,387,973
Ensembl chr 5:124,256,753...124,387,823
|
|
G |
Pole4 |
polymerase (DNA-directed), epsilon 4 (p12 subunit) |
increases expression |
ISO |
Chlormequat results in increased expression of POLE4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:82,593,513...82,629,985
Ensembl chr 6:82,595,973...82,682,346
|
|
G |
Pou1f1 |
POU domain, class 1, transcription factor 1 |
increases expression |
ISO |
Chlormequat results in increased expression of POU1F1 protein |
CTD |
PMID:38552810 |
|
NCBI chr16:65,317,398...65,331,904
Ensembl chr16:65,317,397...65,331,183
|
|
G |
Pphln1 |
periphilin 1 |
increases expression |
ISO |
Chlormequat results in increased expression of PPHLN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:93,296,243...93,389,794
Ensembl chr15:93,296,231...93,389,391
|
|
G |
Prkaca |
protein kinase, cAMP dependent, catalytic, alpha |
affects expression |
ISO |
Chlormequat affects the expression of PRKACA protein |
CTD |
PMID:38552810 |
|
NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072
|
|
G |
Prkar1b |
protein kinase, cAMP dependent regulatory, type I beta |
increases expression |
ISO |
Chlormequat results in increased expression of PRKAR1B protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:139,003,059...139,136,458
Ensembl chr 5:139,003,061...139,135,756
|
|
G |
Psmb7 |
proteasome (prosome, macropain) subunit, beta type 7 |
increases expression |
ISO |
Chlormequat results in increased expression of PSMB7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:38,478,058...38,533,964
Ensembl chr 2:38,478,048...38,534,099
|
|
G |
Rab6a |
RAB6A, member RAS oncogene family |
increases expression |
ISO |
Chlormequat results in increased expression of RAB6A protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:100,256,778...100,290,475
Ensembl chr 7:100,256,617...100,290,475
|
|
G |
Rad17 |
RAD17 checkpoint clamp loader component |
increases expression |
ISO |
Chlormequat results in increased expression of RAD17 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:100,753,672...100,787,569
Ensembl chr13:100,753,672...100,787,559
|
|
G |
Rhoq |
ras homolog family member Q |
increases expression |
ISO |
Chlormequat results in increased expression of RHOQ protein |
CTD |
PMID:34958886 |
|
NCBI chr17:87,270,539...87,307,497
Ensembl chr17:87,270,510...87,307,497
|
|
G |
Rnf113a1 |
ring finger protein 113A1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of RNF113A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:36,454,875...36,456,120
Ensembl chr X:36,454,898...36,456,120
|
|
G |
Rnf185 |
ring finger protein 185 |
increases expression multiple interactions |
ISO |
Chlormequat results in increased expression of RNF185 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein] |
CTD |
PMID:34958886 |
|
NCBI chr11:3,365,973...3,402,956
Ensembl chr11:3,365,982...3,402,363
|
|
G |
Rspry1 |
ring finger and SPRY domain containing 1 |
increases expression |
ISO |
Chlormequat results in increased expression of RSPRY1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:95,328,569...95,386,905
Ensembl chr 8:95,328,565...95,386,903
|
|
G |
Rtn1 |
reticulon 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of RTN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:72,258,523...72,455,828
Ensembl chr12:72,258,526...72,455,828
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
increases expression |
ISO |
Chlormequat results in increased expression of S100A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:90,418,341...90,421,637
Ensembl chr 3:90,418,341...90,421,699
|
|
G |
Samd8 |
sterile alpha motif domain containing 8 |
increases expression |
ISO |
Chlormequat results in increased expression of SAMD8 protein |
CTD |
PMID:34958886 |
|
NCBI chr14:21,800,599...21,848,794
Ensembl chr14:21,800,599...21,848,794
|
|
G |
Sar1a |
secretion associated Ras related GTPase 1A |
increases expression |
ISO |
Chlormequat results in increased expression of SAR1A protein |
CTD |
PMID:34958886 |
|
NCBI chr10:61,516,096...61,529,076
Ensembl chr10:61,516,078...61,529,076
|
|
G |
Shroom1 |
shroom family member 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of SHROOM1 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:53,347,904...53,358,593
Ensembl chr11:53,348,032...53,358,593
|
|
G |
Ski |
ski sarcoma viral oncogene homolog (avian) |
increases expression |
ISO |
Chlormequat results in increased expression of SKI protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:155,238,532...155,307,536
Ensembl chr 4:155,238,532...155,307,049
|
|
G |
Slc48a1 |
solute carrier family 48 (heme transporter), member 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of SLC48A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:97,682,246...97,690,573
Ensembl chr15:97,676,401...97,690,573
|
|
G |
Slit3 |
slit guidance ligand 3 |
increases expression |
ISO |
Chlormequat results in increased expression of SLIT3 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:35,012,283...35,599,334
Ensembl chr11:35,012,051...35,599,334
|
|
G |
Slu7 |
SLU7 splicing factor homolog (S. cerevisiae) |
increases expression |
ISO |
Chlormequat results in increased expression of SLU7 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:43,324,550...43,338,809
Ensembl chr11:43,324,571...43,338,808
|
|
G |
Smim26 |
small integral membrane protein 26 |
decreases expression |
ISO |
Chlormequat results in decreased expression of SMIM26 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:144,435,985...144,437,286
Ensembl chr 2:144,435,974...144,437,286
|
|
G |
Spns1 |
SPNS lysolipid transporter 1, lysophospholipid |
increases expression |
ISO |
Chlormequat results in increased expression of SPNS1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:125,969,232...125,977,179
Ensembl chr 7:125,969,232...125,976,622
|
|
G |
Sppl2b |
signal peptide peptidase like 2B |
increases expression |
ISO |
Chlormequat results in increased expression of SPPL2B protein |
CTD |
PMID:34958886 |
|
NCBI chr10:80,691,067...80,704,542
Ensembl chr10:80,691,109...80,704,542
|
|
G |
Sst |
somatostatin |
affects expression |
ISO |
Chlormequat affects the expression of SST protein |
CTD |
PMID:38552810 |
|
NCBI chr16:23,708,327...23,710,041
Ensembl chr16:23,708,323...23,709,708
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ST3GAL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:66,974,724...67,048,575
Ensembl chr15:66,974,724...67,048,679
|
|
G |
St7l |
suppression of tumorigenicity 7-like |
decreases expression |
ISO |
Chlormequat results in decreased expression of ST7L protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:104,771,822...104,837,384
Ensembl chr 3:104,771,321...104,837,380
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
Chlormequat results in decreased expression of STAR protein |
CTD |
PMID:29447956 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Stk26 |
serine/threonine kinase 26 |
increases expression |
ISO |
Chlormequat results in increased expression of STK26 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:49,930,052...49,981,980
Ensembl chr X:49,929,924...49,981,974
|
|
G |
Susd2 |
sushi domain containing 2 |
increases expression |
ISO |
Chlormequat results in increased expression of SUSD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:75,472,453...75,479,842
Ensembl chr10:75,472,540...75,479,842
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Chlormequat results in increased expression of TAF7 protein |
CTD |
PMID:34958886 |
|
NCBI chr18:37,773,544...37,777,257
Ensembl chr18:37,773,544...37,777,257
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
increases expression |
ISO |
Chlormequat results in increased expression of TCAF1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:42,644,933...42,687,065
Ensembl chr 6:42,644,936...42,687,022
|
|
G |
Tceanc |
transcription elongation factor A (SII) N-terminal and central domain containing |
decreases expression |
ISO |
Chlormequat results in decreased expression of TCEANC protein |
CTD |
PMID:34958886 |
|
NCBI chr X:165,282,806...165,301,594
Ensembl chr X:165,282,808...165,301,563
|
|
G |
Tent2 |
terminal nucleotidyltransferase 2 |
increases expression |
ISO |
Chlormequat results in increased expression of TENT2 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:93,282,363...93,330,662
Ensembl chr13:93,282,790...93,328,893
|
|
G |
Them4 |
thioesterase superfamily member 4 |
decreases expression |
ISO |
Chlormequat results in decreased expression of THEM4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:94,217,415...94,239,847
Ensembl chr 3:94,217,396...94,239,847
|
|
G |
Thoc6 |
THO complex 6 |
increases expression |
ISO |
Chlormequat results in increased expression of THOC6 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:23,887,592...23,892,891
Ensembl chr17:23,887,588...23,892,856
|
|
G |
Tirap |
toll-interleukin 1 receptor (TIR) domain-containing adaptor protein |
increases expression |
ISO |
Chlormequat results in increased expression of TIRAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:35,095,687...35,111,587
Ensembl chr 9:35,095,847...35,111,587
|
|
G |
Tkt |
transketolase |
increases expression |
ISO |
Chlormequat results in increased expression of TKT protein |
CTD |
PMID:34958886 |
|
NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677
|
|
G |
Tmem106c |
transmembrane protein 106C |
increases expression |
ISO |
Chlormequat results in increased expression of TMEM106C protein |
CTD |
PMID:34958886 |
|
NCBI chr15:97,862,077...97,868,158
Ensembl chr15:97,862,081...97,868,156
|
|
G |
Tmem184c |
transmembrane protein 184C |
decreases expression |
ISO |
Chlormequat results in decreased expression of TMEM184C protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:78,322,607...78,337,343
Ensembl chr 8:78,322,611...78,337,327
|
|
G |
Tmem208 |
transmembrane protein 208 |
increases expression |
ISO |
Chlormequat results in increased expression of TMEM208 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:106,052,980...106,062,117
Ensembl chr 8:106,052,986...106,061,851
|
|
G |
Tmem222 |
transmembrane protein 222 |
increases expression |
ISO |
Chlormequat results in increased expression of TMEM222 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:132,993,356...133,005,101
Ensembl chr 4:132,993,356...133,005,103
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
affects expression |
ISO |
Chlormequat affects the expression of TNFSF11 mRNA |
CTD |
PMID:28214531 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Tra2a |
transformer 2 alpha |
increases expression |
ISO |
Chlormequat results in increased expression of TRA2A protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:49,220,855...49,241,182
Ensembl chr 6:49,220,858...49,240,967
|
|
G |
Tram2 |
translocating chain-associating membrane protein 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of TRAM2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:21,071,621...21,149,449
Ensembl chr 1:21,066,523...21,149,453
|
|
G |
Trp53i11 |
transformation related protein 53 inducible protein 11 |
increases expression |
ISO |
Chlormequat results in increased expression of TP53I11 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:93,017,694...93,032,102
Ensembl chr 2:93,017,893...93,032,104
|
|
G |
Ttc12 |
tetratricopeptide repeat domain 12 |
increases expression |
ISO |
Chlormequat results in increased expression of TTC12 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:49,348,261...49,397,572
Ensembl chr 9:49,348,263...49,397,525
|
|
G |
Ube2d1 |
ubiquitin-conjugating enzyme E2D 1 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein] |
CTD |
PMID:34958886 |
|
NCBI chr10:71,090,810...71,121,048
Ensembl chr10:71,090,810...71,121,092
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
decreases expression |
ISO |
Chlormequat results in decreased expression of UCP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Wdr74 |
WD repeat domain 74 |
increases expression |
ISO |
Chlormequat results in increased expression of WDR74 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:8,713,159...8,717,988
Ensembl chr19:8,713,191...8,717,988
|
|
G |
Wsb2 |
WD repeat and SOCS box-containing 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of WSB2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:117,495,370...117,516,666
Ensembl chr 5:117,495,369...117,516,666
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ZEB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr18:5,591,330...5,775,468
Ensembl chr18:5,591,860...5,775,467
|
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
EXP |
cocaine hydrochloride decreases expression of Bmal1 mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333
|
|
G |
Clock |
clock circadian regulator |
increases expression |
EXP |
cocaine hydrochloride increases expression of Clock mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 5:76,357,715...76,452,675
Ensembl chr 5:76,357,715...76,452,639
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression increases expression |
EXP |
cocaine hydrochloride decreases expression of Cry1 mRNA in caudate-putamen cocaine hydrochloride increases expression of Cry1 mRNA in hippocampal formation |
RGD |
PMID:15994025 PMID:15994025 |
RGD:405866347, RGD:405866347 |
NCBI chr10:84,967,564...85,020,918
Ensembl chr10:84,967,564...85,020,928
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
decreases expression |
EXP |
cocaine hydrochloride decreases expression of Cry2 mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866347 |
NCBI chr 2:92,233,991...92,264,426
Ensembl chr 2:92,233,991...92,264,388
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
decreases expression |
EXP |
cocaine hydrochloride decreases expression of hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866347 |
NCBI chr 1:39,233,013...39,402,321
Ensembl chr 1:39,232,812...39,402,317
|
|
G |
Per1 |
period circadian clock 1 |
increases expression |
EXP |
cocaine hydrochloride increases expression of Per1 mRNA in hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr11:68,985,934...69,000,791
Ensembl chr11:68,986,043...69,000,786
|
|
G |
Per2 |
period circadian clock 2 |
increases expression decreases expression |
EXP |
ocaine hydrochloride increases expression of Per2 mRNA in hippocampal formation cocaine hydrochloride decreases expression of Per2 mRNA in caudate-putamen |
RGD |
PMID:15994025 PMID:15994025 |
RGD:405866348, RGD:405866348 |
NCBI chr 1:91,343,699...91,387,028
Ensembl chr 1:91,343,704...91,387,046
|
|
G |
Per3 |
period circadian clock 3 |
increases expression |
EXP |
cocaine hydrochloride increases expression of Per3 mRNA in hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 4:151,081,475...151,129,167
Ensembl chr 4:151,088,109...151,129,122
|
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
decreases expression |
ISO |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions increases expression |
EXP |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
EXP |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Diethylhexyl Phthalate results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:37536456 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of ABCB1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
multiple interactions decreases expression |
ISO |
Colforsin inhibits the reaction [Doxorubicin results in increased expression of ABCB4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
ISO |
Colforsin results in increased expression of ABCC2 mRNA; Colforsin results in increased expression of ABCC2 protein |
CTD |
PMID:19580841 PMID:26049102 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of ABCC4 mRNA Valproic Acid inhibits the reaction [Colforsin results in decreased expression of ABCC4 mRNA] |
CTD |
PMID:37385477 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of ABCG2 mRNA Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] |
CTD |
PMID:19580841 PMID:30610963 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
increases phosphorylation |
EXP |
Colforsin results in increased phosphorylation of ACACA protein |
CTD |
PMID:18390901 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
ISO |
Colforsin results in increased activity of ACHE protein; Colforsin results in increased activity of ACHE protein alternative form Colforsin results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
increases expression |
ISO |
Colforsin results in increased expression of ACSL3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of ACTA2 protein Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:21603974 PMID:27590029 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADAM12 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr 7:133,484,928...133,826,859
Ensembl chr 7:133,484,928...133,833,875
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001
|
|
G |
Adcy5 |
adenylate cyclase 5 |
multiple interactions |
EXP |
ADCY5 protein results in increased susceptibility to [Colforsin co-treated with Quinpirole] |
CTD |
PMID:12223546 |
|
NCBI chr16:34,974,933...35,126,108
Ensembl chr16:34,975,247...35,126,108
|
|
G |
Adcy6 |
adenylate cyclase 6 |
affects response to substance |
EXP |
ADCY6 protein affects the susceptibility to Colforsin |
CTD |
PMID:12393090 |
|
NCBI chr15:98,484,982...98,508,119
Ensembl chr15:98,487,854...98,507,957
|
|
G |
Adcy9 |
adenylate cyclase 9 |
increases activity multiple interactions |
EXP |
Colforsin results in increased activity of ADCY9 protein [Colforsin co-treated with Miconazole] results in increased activity of ADCY9 protein |
CTD |
PMID:30607468 |
|
NCBI chr16:4,102,750...4,255,094
Ensembl chr16:4,105,393...4,238,362
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA] |
CTD |
PMID:38296531 |
|
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
|
|
G |
Adra1a |
adrenergic receptor, alpha 1a |
multiple interactions |
ISO |
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium] |
CTD |
PMID:19419905 |
|
NCBI chr14:66,872,705...67,009,549
Ensembl chr14:66,872,700...67,008,617
|
|
G |
Adra2c |
adrenergic receptor, alpha 2c |
multiple interactions affects localization increases expression |
ISO |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA] |
CTD |
PMID:24701590 |
|
NCBI chr 5:35,435,910...35,439,107
Ensembl chr 5:35,435,663...35,439,107
|
|
G |
Adrb1 |
adrenergic receptor, beta 1 |
affects response to substance multiple interactions |
ISO |
ADRB1 protein polymorphism affects the susceptibility to Colforsin [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] |
CTD |
PMID:14502278 PMID:19419905 |
|
NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545
|
|
G |
Adrb2 |
adrenergic receptor, beta 2 |
multiple interactions increases expression increases phosphorylation |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] Colforsin results in increased expression of ADRB2 mRNA Colforsin results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 PMID:19419905 PMID:24705868 |
|
NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030
|
|
G |
Adrb3 |
adrenergic receptor, beta 3 |
decreases expression |
EXP |
Colforsin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:10725275 |
|
NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions affects localization |
ISO EXP |
[Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA] |
CTD |
PMID:15972329 PMID:17329248 PMID:17823304 PMID:23291558 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akap13 |
A kinase anchor protein 13 |
multiple interactions |
ISO |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]; AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:24701590 |
|
NCBI chr 7:75,105,271...75,404,357
Ensembl chr 7:75,105,282...75,404,357
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases expression |
ISO |
Colforsin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:28235592 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16339297 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Akt2 |
thymoma viral proto-oncogene 2 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251
|
|
G |
Akt3 |
thymoma viral proto-oncogene 3 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:176,847,642...177,091,688
Ensembl chr 1:176,847,639...177,085,769
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] |
CTD |
PMID:27590029 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 1:87,025,724...87,029,328
Ensembl chr 1:87,025,724...87,029,328
|
|
G |
Aoc1 |
amine oxidase, copper-containing 1 |
increases activity |
ISO |
Colforsin results in increased activity of AOC1 protein |
CTD |
PMID:2860926 |
|
NCBI chr 6:48,872,189...48,886,122
Ensembl chr 6:48,849,830...48,886,122
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of APPBP2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:85,082,134...85,125,946
Ensembl chr11:85,078,088...85,125,956
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK2 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein]; Colforsin promotes the reaction [Metribolone results in increased activity of AR protein] Colforsin results in increased expression of AR protein |
CTD |
PMID:16751804 PMID:17219378 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Areg |
amphiregulin |
increases expression multiple interactions |
ISO EXP |
Colforsin results in increased expression of AREG mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein] |
CTD |
PMID:15284208 PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 7:99,184,356...99,255,979
Ensembl chr 7:99,184,673...99,255,978
|
|
G |
Atxn3 |
ataxin 3 |
decreases expression |
ISO |
Colforsin results in decreased expression of ATXN3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of BCL2 mRNA; S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of BCL2 mRNA] |
CTD |
PMID:36336211 PMID:37544576 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions increases expression |
ISO EXP |
1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF mRNA]; 1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF protein] Colforsin results in increased expression of BDNF mRNA; Colforsin results in increased expression of BDNF protein |
CTD |
PMID:19189864 PMID:35917217 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases expression |
EXP |
Colforsin results in increased expression of BMAL1 mRNA |
CTD |
PMID:30524225 |
|
NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278
|
|
G |
C4a |
complement C4A (Rodgers blood group) |
multiple interactions |
ISO |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of C4A mRNA |
CTD |
PMID:35892601 |
|
NCBI chr17:35,028,069...35,042,436
Ensembl chr17:35,028,069...35,042,440
|
|
G |
Cacna1g |
calcium channel, voltage-dependent, T type, alpha 1G subunit |
multiple interactions |
ISO |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein] |
CTD |
PMID:17110049 |
|
NCBI chr11:94,299,217...94,365,226
Ensembl chr11:94,299,217...94,365,024
|
|
G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
multiple interactions |
ISO |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein] |
CTD |
PMID:17110049 |
|
NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759
|
|
G |
Cacna1i |
calcium channel, voltage-dependent, alpha 1I subunit |
multiple interactions |
ISO |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein] |
CTD |
PMID:17110049 |
|
NCBI chr15:80,171,439...80,282,493
Ensembl chr15:80,171,439...80,282,480
|
|
G |
Calcrl |
calcitonin receptor-like |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr 2:84,160,970...84,255,786
Ensembl chr 2:84,160,970...84,255,755
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2, beta |
increases expression |
ISO |
Colforsin results in increased expression of CAMKK2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:122,856,064...122,918,295
Ensembl chr 5:122,869,233...122,917,472
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of CASK protein Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein] |
CTD |
PMID:20067577 |
|
NCBI chr X:13,383,319...13,713,020
Ensembl chr X:13,383,319...13,717,606
|
|
G |
Casp1 |
caspase 1 |
increases activity |
ISO |
Colforsin results in increased activity of CASP1 mRNA; Colforsin results in increased activity of CASP1 protein |
CTD |
PMID:21832250 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO EXP |
Colforsin results in increased activity of CASP3 protein Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein] Colforsin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:16396944 PMID:20131233 PMID:21745194 PMID:31278978 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:29283200 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cd55 |
CD55 molecule, decay accelerating factor for complement |
multiple interactions increases expression |
ISO |
3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Colforsin results in increased expression of CD55 mRNA] |
CTD |
PMID:22553215 |
|
NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481
|
|
G |
Cdc6 |
cell division cycle 6 |
increases expression |
ISO |
Colforsin results in increased expression of CDC6 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:98,798,627...98,814,768
Ensembl chr11:98,798,627...98,814,766
|
|
G |
Cdh1 |
cadherin 1 |
affects activity decreases expression increases expression |
ISO |
Colforsin affects the activity of CDH1 protein Colforsin results in decreased expression of CDH1 protein Colforsin results in increased expression of CDH1 protein |
CTD |
PMID:10413674 PMID:30983542 PMID:38301883 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdrt4 |
CMT1A duplicated region transcript 4 |
multiple interactions |
ISO |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of CDRT4 mRNA |
CTD |
PMID:35892601 |
|
NCBI chr11:62,842,019...62,883,921
Ensembl chr11:62,842,019...62,883,921
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
EXP ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA] Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein] Colforsin results in increased expression of CEBPA protein |
CTD |
PMID:17407152 PMID:21832167 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
EXP ISO |
Colforsin results in increased expression of CEBPB mRNA [Atrazine co-treated with Colforsin] results in increased expression of CEBPB protein |
CTD |
PMID:14684744 PMID:25253736 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
affects localization multiple interactions increases activity |
ISO EXP |
Colforsin affects the localization of CFTR protein [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein] 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 6-hydroxy-10-chlorobenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CFTR protein; [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [Colforsin co-treated with NS 004] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]; Colforsin binds to and results in decreased activity of CFTR protein; Colforsin promotes the reaction [CFTR protein affects the export of Chlorides]; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein]; Colforsin results in increased phosphorylation of and results in increased activity of CFTR protein; fenamic acid inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; fenamic acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; geldanamycin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; Ozone inhibits the reaction [Colforsin results in increased activity of CFTR protein]; Thapsigargin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; VRT 532 analog promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]; VRT 532 promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form] Colforsin analog results in increased activity of CFTR protein mutant form; Colforsin results in increased activity of CFTR protein; Colforsin results in increased activity of CFTR protein mutant form |
CTD |
PMID:12519745 PMID:12914781 PMID:14502435 PMID:14967738 PMID:15163550 PMID:15194485 PMID:15246976 PMID:15389550 PMID:15517342 PMID:15763242 PMID:15790911 PMID:15986093 PMID:15994425 PMID:16027156 PMID:16038730 PMID:17596272 PMID:18230692 PMID:19061877 PMID:21724857 PMID:22074181 PMID:32374624 PMID:33872679 More...
|
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Cga |
glycoprotein hormones, alpha subunit |
increases secretion increases expression multiple interactions |
ISO EXP |
Colforsin results in increased secretion of CGA protein Colforsin results in increased expression of CGA protein Colforsin results in increased expression of CGA mRNA Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; perfluorobutanesulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein]; perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein] Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:8404651 PMID:16503475 PMID:20378682 PMID:33144174 |
|
NCBI chr 4:34,893,779...34,907,374
Ensembl chr 4:34,893,779...34,907,370
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
EXP |
Colforsin results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 6:113,401,595...113,412,721
Ensembl chr 6:113,401,595...113,412,721
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance increases activity |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR1 protein affects the susceptibility to Colforsin |
CTD |
PMID:27429655 PMID:27527584 PMID:28861508 PMID:31154070 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions increases activity affects response to substance |
ISO EXP |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR2 protein affects the susceptibility to Colforsin |
CTD |
PMID:17558435 PMID:27429655 PMID:27527584 PMID:28861508 PMID:30504240 PMID:31154070 More...
|
|
NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases activity increases expression increases phosphorylation multiple interactions |
EXP ISO |
Colforsin results in increased activity of CREB1 protein Colforsin results in increased expression of CREB1 mRNA; Colforsin results in increased expression of CREB1 protein modified form Colforsin results in increased phosphorylation of CREB1 protein 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Colforsin inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CREB1 protein modified form]; Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]; Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; Colforsin results in increased phosphorylation of and results in increased activity of CREB1 protein [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased activity of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:10908723 PMID:11113530 PMID:15522277 PMID:17141199 PMID:17322281 PMID:17460731 PMID:17680988 PMID:18004999 PMID:20512473 PMID:21745194 PMID:23292070 PMID:24701590 PMID:27509375 PMID:27590029 PMID:28051915 PMID:28601556 PMID:29179997 PMID:30610963 PMID:35917217 More...
|
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein] |
CTD |
PMID:16166624 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
ISO |
Colforsin results in increased expression of CREM mRNA; Colforsin results in increased expression of CREM mRNA alternative form; Colforsin results in increased expression of CREM protein |
CTD |
PMID:8810303 PMID:12791704 |
|
NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases secretion |
ISO |
CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Testosterone] [perfluorooctane sulfonic acid co-treated with Colforsin] results in increased expression of CRH mRNA Colforsin results in increased secretion of CRH protein |
CTD |
PMID:2153673 PMID:33144174 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Crls1 |
cardiolipin synthase 1 |
increases expression |
ISO |
Colforsin results in increased expression of CRLS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:132,688,557...132,708,706
Ensembl chr 2:132,688,586...132,708,705
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
ISO |
Colforsin inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr 9:50,657,251...50,667,936
Ensembl chr 9:50,662,625...50,667,936
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
EXP ISO |
Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA] [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; [nickel sulfate co-treated with Colforsin] results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]] |
CTD |
PMID:17823304 PMID:19063610 PMID:23526216 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression multiple interactions increases expression |
ISO EXP |
Colforsin affects the expression of CYP11A1 mRNA [Colforsin co-treated with Zearalenone] results in increased expression of CYP11A1 mRNA Colforsin results in increased expression of CYP11A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP11A1 mRNA; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of CYP11A1 mRNA] [Atrazine co-treated with Colforsin] results in increased expression of CYP11A1 mRNA; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein] |
CTD |
PMID:14691014 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 PMID:22446829 PMID:22948218 PMID:25253736 PMID:25765474 PMID:25871633 PMID:26783879 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp11b1 |
cytochrome P450, family 11, subfamily b, polypeptide 1 |
increases activity multiple interactions |
EXP |
Colforsin results in increased activity of CYP11B1 protein 1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene inhibits the reaction [Colforsin results in increased activity of CYP11B1 protein]; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Colforsin results in increased activity of CYP11B1 protein]; Etomidate inhibits the reaction [Colforsin results in increased activity of CYP11B1 protein] |
CTD |
PMID:18651133 |
|
NCBI chr15:74,706,741...74,713,492
Ensembl chr15:74,705,974...74,713,492
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of CYP11B2 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B2 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B2 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:16935330 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 PMID:22446829 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr15:74,722,467...74,728,080
Ensembl chr15:74,722,467...74,728,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Colforsin results in increased expression of CYP17A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP17A1 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:15625562 PMID:15886251 PMID:16935330 PMID:17080404 PMID:20726872 PMID:22446829 PMID:22461451 PMID:23370353 PMID:25871633 PMID:28235592 PMID:31100596 PMID:31557376 More...
|
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO EXP |
Colforsin results in increased activity of CYP19A1 protein Colforsin results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; [Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Estradiol; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Testosterone; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Atrazine inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased activity of CYP19A1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; ZNF461 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] Colforsin results in increased expression of CYP19A1 mRNA; Colforsin results in increased expression of CYP19A1 protein |
CTD |
PMID:14691014 PMID:16357189 PMID:16935330 PMID:16996190 PMID:17080404 PMID:18936084 PMID:19822197 PMID:20087668 PMID:20723554 PMID:20726872 PMID:22446829 PMID:22461451 PMID:22948218 PMID:24361490 PMID:25765474 PMID:25871633 PMID:28235592 PMID:28859905 PMID:29701941 PMID:31100596 PMID:37551828 More...
|
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects expression |
ISO EXP |
Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] Valproic Acid affects the reaction [Colforsin affects the expression of CYP1A1 mRNA] Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:15710352 PMID:20726872 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP ISO |
Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein] |
CTD |
PMID:1849469 PMID:15710352 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
Colforsin results in increased expression of CYP1B1 mRNA; Colforsin results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp21a1 |
cytochrome P450, family 21, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[Colforsin co-treated with Ketoconazole] results in decreased expression of CYP21A2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP21A2 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP21A2 mRNA]; daidzein inhibits the reaction [Colforsin results in increased expression of CYP21A2 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP21A2 mRNA] |
CTD |
PMID:16935330 PMID:20726872 PMID:21256172 PMID:22446829 PMID:23370353 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr17:35,020,322...35,023,400
Ensembl chr17:35,020,322...35,023,535
|
|
G |
Cyp2a5 |
cytochrome P450, family 2, subfamily a, polypeptide 5 |
increases expression |
EXP |
Colforsin results in increased expression of CYP2A5 mRNA |
CTD |
PMID:11162586 |
|
NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:37544576 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Dbh |
dopamine beta hydroxylase |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Colforsin inhibits the reaction [Simazine results in decreased expression of DBH protein] Colforsin results in increased expression of DBH protein |
CTD |
PMID:14550852 |
|
NCBI chr 2:27,055,519...27,073,216
Ensembl chr 2:27,055,245...27,073,212
|
|
G |
Dct |
dopachrome tautomerase |
increases expression |
ISO |
Colforsin results in increased expression of DCT mRNA; Colforsin results in increased expression of DCT protein |
CTD |
PMID:17460731 PMID:28601556 |
|
NCBI chr14:118,250,202...118,289,658
Ensembl chr14:118,250,202...118,289,656
|
|
G |
Dio2 |
deiodinase, iodothyronine, type II |
increases activity multiple interactions increases expression |
EXP ISO |
Colforsin results in increased activity of DIO2 protein Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]] |
CTD |
PMID:18420745 PMID:19036883 |
|
NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812
|
|
G |
Dio3 |
deiodinase, iodothyronine type III |
multiple interactions |
ISO |
Colforsin promotes the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA] |
CTD |
PMID:18420745 |
|
NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
|
|
G |
Dnm1l |
dynamin 1-like |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of DNM1L protein PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein] |
CTD |
PMID:24792327 |
|
NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17958328 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Dynll2 |
dynein light chain LC8-type 2 |
increases expression |
ISO |
Colforsin results in increased expression of DYNLL2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:87,870,351...87,892,746
Ensembl chr11:87,870,351...87,878,359
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]; Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] |
CTD |
PMID:32092105 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions decreases expression |
ISO |
Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 mRNA]; Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 protein]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 mRNA]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 protein] Colforsin results in decreased expression of EGR1 mRNA; Colforsin results in decreased expression of EGR1 protein |
CTD |
PMID:29802914 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Eif2b5 |
eukaryotic translation initiation factor 2B, subunit 5 epsilon |
increases expression |
ISO |
Colforsin results in increased expression of EIF2B5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr16:20,317,544...20,328,073
Ensembl chr16:20,317,567...20,328,073
|
|
G |
Eif5a2 |
eukaryotic translation initiation factor 5A2 |
decreases expression |
ISO |
Colforsin results in decreased expression of EIF5A2 mRNA |
CTD |
PMID:30983542 |
|
NCBI chr 3:28,835,426...28,852,995
Ensembl chr 3:28,835,425...28,852,995
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
affects expression multiple interactions |
ISO |
Colforsin affects the expression of EPHX1 mRNA Valproic Acid affects the reaction [Colforsin affects the expression of EPHX1 mRNA] |
CTD |
PMID:20726872 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
decreases expression |
ISO |
Colforsin results in decreased expression of EPS8 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr 6:137,454,242...137,626,262
Ensembl chr 6:137,454,243...137,631,874
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO EXP |
Colforsin results in increased expression of EREG mRNA |
CTD |
PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
decreases expression |
ISO |
Colforsin results in decreased expression of ESR1 mRNA |
CTD |
PMID:31278978 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions decreases expression |
EXP ISO |
Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] Colforsin results in decreased expression of ESR2 mRNA |
CTD |
PMID:20378682 PMID:31278978 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
Colforsin results in increased expression of ESRRA mRNA; Colforsin results in increased expression of ESRRA protein |
CTD |
PMID:20351196 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Evi5 |
ecotropic viral integration site 5 |
increases expression |
ISO |
Colforsin results in increased expression of EVI5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:107,892,661...108,022,973
Ensembl chr 5:107,892,661...108,022,973
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
Colforsin inhibits the reaction [F2 protein results in increased uptake of Manganese] |
CTD |
PMID:2125206 |
|
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
F2r |
coagulation factor II thrombin receptor |
multiple interactions |
EXP |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
EXP |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr 8:73,488,287...73,490,526
Ensembl chr 8:73,488,508...73,490,502
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
Colforsin results in increased expression of FADS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA; [Colforsin co-treated with Leflunomide] results in increased expression of FASN mRNA; [Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA |
CTD |
PMID:30364229 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of FDX1 mRNA ferulic acid analog promotes the reaction [Colforsin results in increased expression of FDX1 mRNA] |
CTD |
PMID:36279966 |
|
NCBI chr 9:51,854,323...51,874,902
Ensembl chr 9:51,854,606...51,874,856
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12533312 PMID:14975937 |
|
NCBI chr13:118,851,199...118,928,651
Ensembl chr13:118,806,327...118,928,651
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Colforsin results in increased expression of FGF2 mRNA; Colforsin results in increased expression of FGF2 protein |
CTD |
PMID:10320526 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
Colforsin results in decreased expression of FGF5 mRNA |
CTD |
PMID:11598998 |
|
NCBI chr 5:98,402,108...98,424,892
Ensembl chr 5:98,402,043...98,424,889
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases activity |
ISO |
Colforsin results in increased activity of FGF8 protein |
CTD |
PMID:15193767 |
|
NCBI chr19:45,724,930...45,731,380
Ensembl chr19:45,725,237...45,731,354
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]] |
CTD |
PMID:22798350 |
|
NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
increases expression |
ISO |
Colforsin results in increased expression of FGFR1 mRNA |
CTD |
PMID:10320526 |
|
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Colforsin results in increased expression of FGFR2 mRNA |
CTD |
PMID:10320526 |
|
NCBI chr 7:129,764,181...129,868,538
Ensembl chr 7:129,764,181...132,725,079
|
|
G |
Fkbp5 |
FK506 binding protein 5 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Dexamethasone results in increased expression of FKBP5 mRNA] |
CTD |
PMID:19255438 |
|
NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
|
|
G |
Flt1 |
FMS-like tyrosine kinase 1 |
increases expression |
ISO |
Colforsin results in increased expression of FLT1 mRNA |
CTD |
PMID:33144174 |
|
NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of FOS protein Dexamethasone inhibits the reaction [Colforsin results in increased expression of FOS protein] |
CTD |
PMID:11113530 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fosb |
FBJ osteosarcoma oncogene B |
increases expression |
ISO |
Colforsin results in increased expression of FOSB mRNA; Colforsin results in increased expression of FOSB protein |
CTD |
PMID:11113530 PMID:17324382 |
|
NCBI chr 7:19,036,621...19,043,970
Ensembl chr 7:19,036,621...19,043,976
|
|
G |
Fshb |
follicle stimulating hormone beta |
increases expression |
ISO |
Colforsin results in increased expression of FSHB mRNA; Colforsin results in increased expression of FSHB protein |
CTD |
PMID:8404651 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr13:114,588,798...114,595,522
Ensembl chr13:114,588,826...114,595,487
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with Colforsin] results in increased expression of G6PC1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of G6PC1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA] |
CTD |
PMID:18972406 PMID:30364229 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
increases expression |
ISO |
Colforsin results in increased expression of GABRA1 |
CTD |
PMID:9147380 |
|
NCBI chr11:42,021,766...42,073,893
Ensembl chr11:42,021,766...42,073,757
|
|
G |
| |